IL167900A - Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease - Google Patents

Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease

Info

Publication number
IL167900A
IL167900A IL167900A IL16790005A IL167900A IL 167900 A IL167900 A IL 167900A IL 167900 A IL167900 A IL 167900A IL 16790005 A IL16790005 A IL 16790005A IL 167900 A IL167900 A IL 167900A
Authority
IL
Israel
Prior art keywords
betamimetics
treatment
pharmaceutical compositions
chronic obstructive
obstructive pulmonary
Prior art date
Application number
IL167900A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL167900(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL167900A publication Critical patent/IL167900A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL167900A 2002-11-15 2005-04-07 Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease IL167900A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (1)

Publication Number Publication Date
IL167900A true IL167900A (en) 2013-06-27

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
IL167900A IL167900A (en) 2002-11-15 2005-04-07 Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease

Country Status (38)

Country Link
EP (2) EP1562603B3 (cg-RX-API-DMAC10.html)
JP (1) JP4317138B2 (cg-RX-API-DMAC10.html)
KR (1) KR101092247B1 (cg-RX-API-DMAC10.html)
CN (3) CN101817800A (cg-RX-API-DMAC10.html)
AR (2) AR041969A1 (cg-RX-API-DMAC10.html)
AT (1) ATE430569T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003285326B2 (cg-RX-API-DMAC10.html)
BE (1) BE2014C016I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0316264B8 (cg-RX-API-DMAC10.html)
CA (1) CA2506082C (cg-RX-API-DMAC10.html)
CO (1) CO5570670A2 (cg-RX-API-DMAC10.html)
CY (2) CY1110500T1 (cg-RX-API-DMAC10.html)
DE (2) DE10253282A1 (cg-RX-API-DMAC10.html)
DK (1) DK1562603T3 (cg-RX-API-DMAC10.html)
EA (1) EA008665B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP055774A (cg-RX-API-DMAC10.html)
ES (1) ES2326878T7 (cg-RX-API-DMAC10.html)
FR (1) FR14C0049I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20050432B1 (cg-RX-API-DMAC10.html)
HU (1) HUS1400011I1 (cg-RX-API-DMAC10.html)
IL (1) IL167900A (cg-RX-API-DMAC10.html)
LT (1) LTC1562603I2 (cg-RX-API-DMAC10.html)
LU (1) LU92433I2 (cg-RX-API-DMAC10.html)
ME (1) ME00354B (cg-RX-API-DMAC10.html)
MX (1) MXPA05005081A (cg-RX-API-DMAC10.html)
MY (1) MY136034A (cg-RX-API-DMAC10.html)
NL (1) NL300650I2 (cg-RX-API-DMAC10.html)
NO (2) NO334314B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ540661A (cg-RX-API-DMAC10.html)
PE (1) PE20040694A1 (cg-RX-API-DMAC10.html)
PL (1) PL212238B1 (cg-RX-API-DMAC10.html)
PT (1) PT1562603E (cg-RX-API-DMAC10.html)
RS (1) RS51607B (cg-RX-API-DMAC10.html)
SI (1) SI1562603T1 (cg-RX-API-DMAC10.html)
TW (1) TWI343812B (cg-RX-API-DMAC10.html)
UA (1) UA81276C2 (cg-RX-API-DMAC10.html)
WO (1) WO2004045618A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502246B (cg-RX-API-DMAC10.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
PL2422786T3 (pl) 2004-04-22 2015-02-27 Boehringer Ingelheim Int Nowe kombinacje środków leczniczych do leczenia chorób dróg oddechowych
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
CA2565243A1 (en) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
EP1917253B1 (de) 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
AU2006311060A1 (en) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2642239A1 (en) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
JP2010500319A (ja) * 2006-08-07 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鏡像体上純粋な新規ベータアゴニスト、それらの製造方法及び医薬としてのそれらの使用
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
JP2010515729A (ja) 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
RU2462460C2 (ru) * 2007-01-25 2012-09-27 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения бетамиметиков
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
EP2906218B1 (en) * 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
ES2667424T3 (es) 2014-04-24 2018-05-10 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
ES2900283T3 (es) 2016-12-20 2022-03-16 Inke Sa Proceso mejorado para la fabricación de clorhidrato de (R)-6-hidroxi-8-[1-hidroxi-2-[2-(4-metoxifenil)-1,1-dimetiletilaminoetil]-2H-1,4-benzoxazin-3(4H)-ona
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
WO2021038426A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2021252577A1 (en) * 2020-06-09 2021-12-16 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
AU5629301A (en) * 2000-04-27 2001-11-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments

Also Published As

Publication number Publication date
EA200500715A1 (ru) 2005-12-29
NO334314B1 (no) 2014-02-03
MXPA05005081A (es) 2005-07-01
KR101092247B1 (ko) 2011-12-12
CN101817800A (zh) 2010-09-01
CN1713914A (zh) 2005-12-28
LTC1562603I2 (lt) 2016-12-12
AU2003285326B2 (en) 2009-06-04
BR0316264A (pt) 2005-10-11
MY136034A (en) 2008-07-31
CO5570670A2 (es) 2005-10-31
PE20040694A1 (es) 2004-11-23
EP2025338A1 (de) 2009-02-18
MEP53608A (en) 2011-05-10
NO20052883L (no) 2005-06-14
SI1562603T1 (sl) 2009-10-31
JP2006508140A (ja) 2006-03-09
BRPI0316264B1 (pt) 2019-04-09
CA2506082C (en) 2011-06-21
PL375270A1 (en) 2005-11-28
ME00354B (me) 2011-10-10
DE10253282A1 (de) 2004-05-27
EA008665B1 (ru) 2007-06-29
AR087241A2 (es) 2014-03-12
UA81276C2 (en) 2007-12-25
PL212238B1 (pl) 2012-08-31
TWI343812B (en) 2011-06-21
NO2014005I1 (no) 2014-03-10
RS51607B (sr) 2011-08-31
ZA200502246B (en) 2006-01-25
CY2014032I2 (el) 2015-12-09
EP1562603B1 (de) 2009-05-06
CY1110500T1 (el) 2015-04-29
BRPI0316264B8 (pt) 2021-05-25
NZ540661A (en) 2007-12-21
RS20050361A (sr) 2007-04-10
HUS1400011I1 (hu) 2022-02-28
DE50311502D1 (de) 2009-06-18
AU2003285326A1 (en) 2004-06-15
KR20050075013A (ko) 2005-07-19
BE2014C016I2 (cg-RX-API-DMAC10.html) 2023-03-07
FR14C0049I1 (cg-RX-API-DMAC10.html) 2014-08-08
AR041969A1 (es) 2005-06-01
DK1562603T3 (da) 2009-09-07
FR14C0049I2 (fr) 2015-07-24
CA2506082A1 (en) 2004-06-03
ATE430569T1 (de) 2009-05-15
JP4317138B2 (ja) 2009-08-19
WO2004045618A2 (de) 2004-06-03
HRP20050432B1 (en) 2012-01-31
HRP20050432A2 (en) 2006-06-30
TW200423943A (en) 2004-11-16
EP1562603B3 (de) 2014-01-08
ES2326878T7 (es) 2014-03-11
ECSP055774A (es) 2005-11-22
CN101735166A (zh) 2010-06-16
ES2326878T3 (es) 2009-10-21
WO2004045618A3 (de) 2004-09-30
NL300650I2 (nl) 2017-11-02
LU92433I2 (fr) 2014-06-24
PT1562603E (pt) 2009-06-18
EP1562603A2 (de) 2005-08-17
CY2014032I1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
IL173908A0 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
ZA200706868B (en) 4-Oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
ZA200701584B (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
IL190338A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
IL179906A0 (en) Novel hydantoin derivatives for the treatment of obstructive airway diseases
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
AU2002356646A1 (en) Pharmaceutical compositions for the pulmonary delivery of aztreonam
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
IL163871A0 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
HU0500145D0 (en) Composition for the treatment of oral diseases
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
HK1086482A (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
AU2003301395A1 (en) Therapeutic agent for chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
FF Patent granted
EXTF Application for patent extension filed

Filing date: 20151112

PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: OLODATEROL (AS HYDROCHLORIDE

Extension date: 20271010

KB Patent renewed
EXTJ Intention to grant a patent extension

Free format text: PRODUCT NAME: OLODATEROL (AS HYDROCHLORIDE)

Extension date: 20270119

EXTG Extension of patent term granted

Extension date: 20270119